AZN•benzinga•
AstraZeneca Announced Global Collaboration With Harbour BioMed To Develop Next-Gen Therapeutic Antibodies, Including $105M Equity Investment, $175M Upfront, Up To $4.4B In Milestones, And Acquisition Of 9.15% Newly Issued Shares Of Harbour BioMed
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 21, 2025 by benzinga